Histologically or cytologically confirmed adenocarcinoma of the prostate. No evidence of neuroendocrine differentiation or small cell features.
Histologically confirmed diagnosis of prostate adenocarcinoma; variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate, are not permitted
Histologic or cytologic diagnosis of adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Histologically confirmed prostate adenocarcinoma without neuroendocrine differentiation or small-cell features
Histologically confirmed metastatic adenocarcinoma of the prostate without histological neuroendocrine differentiation or small cell features
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Histologically confirmed adenocarcinoma of the prostate without signet cell or small cell features
Histologically-confirmed diagnosis of prostate adenocarcinoma; variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate, are not permitted
Histologically or cytologically confirmed adenocarcinoma of the prostate without signet cell, or small cell features.
Progressive castration-resistant metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Histologically or cytologically confirmed carcinoma of the prostate (excluding neuroendocrine differentiation or squamous cell histology)
Histologically or cytologically confirmed carcinoma of the prostate (excluding neuroendocrine differentiation or squamous cell histology)
Histologically confirmed diagnosis of adenocarcinoma of the prostate; histologic variants of prostate cancer comprising of > 50% of the tumor including neuroendocrine features and small cell carcinoma of the prostate are excluded
Histologically confirmed adenocarcinoma of the prostate without morphologic neuroendocrine differentiation or small cell features.
Histologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or small cell features;
Histologically or cytologically confirmed prostate cancer (individuals with primary neuroendocrine carcinoma of prostate are excluded)
Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.
Histologically or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell, or small cell features;
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, or signet cell or small cell features;
Histologically confirmed adenocarcinoma of the prostate without histological variants (including overt neuroendocrine differentiation, small cell neuroendocrine carcinoma features, sarcomatoid features, pure ductal adenocarcinoma, squamous or transitional cell carcinoma)
Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate without > 50% neuroendocrine differentiation or small cell histology
Progressive castration-resistant metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features with high risk for development of metastases, defined as prostate-specific antigen doubling time (PSADT) less than or equal to (<=) 10 months. PSADT is calculated using at least 3 prostate-specific antigen (PSA) values obtained during continuous ADT (androgen deprivation therapy)
Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate without >= 50% neuroendocrine differentiation or small cell histology
Histologically confirmed diagnosis of adenocarcinoma of the prostate; histologic variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate are excluded
Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Expansion Cohort 6: Subjects with metastatic CRPC (adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features) who have radiographically progressed in soft tissue on or after enzalutamide and/or abiraterone acetate for metastatic disease.
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Histologically or cytologically confirmed adenocarcinoma of the prostate without signet ring cell features.
Histologically or cytologically confirmed carcinoma of the bladder of all histologies except neuroendocrine differentiation or squamous cell histology
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Histologically confirmed adenocarcinoma of the prostate without histological variants comprising > 50% of the sample as determined by academic center central review (including neuroendocrine differentiation, small cell, sarcomatoid, ductal adenocarcinoma, squamous or transitional cell carcinoma)
Histologically confirmed diagnosis of adenocarcinoma of the prostate; small cell or neuroendocrine tumors of the prostate are also permitted
Histologically confirmed adenocarcinoma of the prostate; patients with small cell, neuroendocrine, and transitional cell carcinomas are not eligible
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
